Can dual-targeting therapies redefine second-line colorectal cancer treatment in 2026?

Johnson & Johnson’s recent presentation of extended OrigAMI-1 trial data for amivantamab-vmjw in RAS/BRAF wild-type metastatic colorectal cancer adds renewed urgency to a question that oncologists and developers have long circled but never definitively answered: can dual-targeting therapies reshape outcomes in the second-line setting, where resistance undermines current anti-EGFR strategies?

For Johnson & Johnson, the early signs from the OrigAMI-1 study suggest that its bispecific EGFR-MET antibody may offer a more durable treatment option in a landscape dominated by combination chemotherapy and single-pathway inhibitors. What remains is a far more complex challenge involving proving that these results can scale to broader populations, compete commercially against entrenched agents, and satisfy payers seeking real-world cost-effectiveness.

Why second-line colorectal cancer remains a high-friction treatment setting despite decades of therapeutic evolution

Colorectal cancer is the third most commonly diagnosed cancer worldwide, and metastatic disease, especially in the left colon, presents a difficult therapeutic terrain once first-line regimens fail. Historically, second-line treatment has relied on agents such as FOLFIRI or FOLFOX in combination with anti-EGFR monoclonal antibodies like cetuximab or panitumumab for RAS/BRAF wild-type tumors. While this approach remains standard of care, its limitations are well documented. Median progression-free survival is often no longer than six months, and resistance typically develops quickly through alternate signaling pathways such as MET amplification.

The second-line setting has become a proving ground for developers of precision-targeted therapies and bispecific agents seeking to block known resistance escape routes. But the bar is high. A new therapy must outperform the limited but predictable benefits of anti-EGFR agents, offer manageable toxicity, and ideally demonstrate survival benefit, none of which are easily achieved in a patient population that is often heavily pretreated.

What amivantamab’s early data reveal about the dual inhibition strategy in colorectal cancer

In the updated OrigAMI-1 trial results presented at the 2026 ASCO GI Symposium, Johnson & Johnson reported that amivantamab-vmjw, its fully human bispecific antibody targeting EGFR and MET, delivered an overall response rate of 51 percent across 43 patients when combined with either FOLFOX or FOLFIRI chemotherapy. In the second-line subgroup specifically, response rates reached 44 percent with a median duration of response of 7.4 months, and over one-third of patients remained on therapy beyond a year. Three patients continued beyond two years.

These results are not merely incremental. If they are replicated in Phase 3 trials, they could support a clinical positioning argument that dual-targeting EGFR and MET can delay resistance and extend therapeutic response. The liver metastases subgroup, which typically sees poorer outcomes, also showed strong responses and longer progression-free survival.

The low rate of treatment discontinuations, at just 9 percent, supports the argument that amivantamab’s risk-benefit profile may justify broader use, especially in patients with molecular profiles predictive of MET-mediated resistance.

How dual-targeting compares with traditional anti-EGFR options and emerging resistance modulators

Existing monoclonal antibodies like cetuximab and panitumumab act on EGFR alone and have shown efficacy in first- and second-line settings. However, their Achilles heel has always been the emergence of acquired resistance, often through MET amplification or KRAS mutations. Once resistance develops, these agents lose effectiveness rapidly, and patients are often cycled through standard chemotherapeutics with diminishing returns.

Amivantamab’s targeting of both EGFR and MET in a single agent seeks to preempt this resistance. The dual blockade concept is not new. Prior combinations of EGFR and MET inhibitors have been trialed, but few have shown the same level of durable efficacy in a solid tumor as complex and heterogeneous as colorectal cancer.

Other agents are in development that attempt to address these resistance pathways through different mechanisms. MET inhibitors such as capmatinib and tepotinib have shown promise in other cancers but remain largely untested in colorectal settings. Antibody-drug conjugates are also entering the picture, with multiple pipelines investigating payload delivery to EGFR or HER2-expressing colorectal cancer subtypes, though none have yet supplanted bispecifics in this setting.

Checkpoint inhibitors have shown efficacy in microsatellite instability-high or mismatch repair-deficient tumors but are ineffective in the majority of colorectal cancer cases, which are microsatellite stable. This leaves a large patient population still dependent on chemotherapy and EGFR-based regimens, and potentially open to conversion if a bispecific shows better durability.

Why subcutaneous formulation and trial scalability will matter just as much as efficacy

Johnson & Johnson is not only betting on the intravenous formulation of amivantamab. Its ongoing OrigAMI-2 and OrigAMI-3 trials are evaluating a subcutaneous version of the drug in combination with chemotherapy. If this version matches the efficacy and tolerability of the IV formulation, it would offer a significant operational advantage. Subcutaneous biologics are faster to administer, require fewer healthcare resources, and are more compatible with community oncology settings where infusion capacity can be a constraint.

This strategy mirrors trends seen with agents such as Roche’s Phesgo and Genmab’s epcoritamab, both of which use subcutaneous delivery to increase accessibility. For Johnson & Johnson, success in these studies would allow them to meet growing demand for therapy simplification without compromising efficacy, a critical factor in driving payer adoption and institutional preference.

What regulatory, commercial, and execution hurdles still lie ahead

Despite the promising signal, several challenges remain. The OrigAMI-1 study is a relatively small Phase 1b/2 trial with limited generalizability. Its results will need to be validated in larger randomized Phase 3 trials before regulatory submission. The patient selection criteria, limited to RAS/BRAF wild-type tumors with no prior EGFR exposure, may also restrict the eligible population and complicate payer coverage decisions.

Pricing and reimbursement pressures are also likely. Anti-EGFR therapies are already entrenched and relatively inexpensive in some markets. A dual-targeting biologic will need to demonstrate not just clinical superiority but also cost-effectiveness, particularly in systems such as the United Kingdom’s National Health Service or under U.S. Medicare reimbursement models.

Resistance to amivantamab itself could emerge over time. While the dual blockade of EGFR and MET may delay resistance, it does not eliminate it. Long-term follow-up data will be essential to determine whether new escape pathways develop and whether combination strategies will need to evolve accordingly.

What this means for the broader pipeline of second-line colorectal cancer innovation

If amivantamab succeeds in demonstrating consistent progression-free and overall survival benefits in second-line metastatic colorectal cancer, it will almost certainly spark broader interest in dual-targeting approaches. Developers of trispecific antibodies, antibody-drug conjugates, and other platform technologies will be watching closely, especially those aiming to address the immunologically cold, microsatellite-stable colorectal cancer segment.

Companies such as Amgen, Regeneron, and Sanofi are already investing heavily in bispecific formats across other tumor types. Success for Johnson & Johnson in metastatic colorectal cancer could signal that the platform is viable even in high-volume, high-resistance indications and not just niche mutations or orphan settings.

The commercial implications are just as significant. Colorectal cancer represents one of the largest global oncology markets by patient volume. Gaining even a modest share of second-line patients would represent a meaningful revenue opportunity, especially if subcutaneous delivery allows Johnson & Johnson to move beyond academic centers and into broader community use.